Related Experiment Videos
Levetiracetam monotherapy for primary generalised epilepsy
1Beth Israel-Singer Division, 170 East End Avenue at 87th Street, New York, NY 10128, USA. jcohen@ehpnet.org
Seizure
|March 26, 2003
Summary
Levetiracetam effectively treated refractory primary generalised epilepsy in three patients, achieving seizure freedom for at least six months. This new antiepileptic drug (AED) offers a promising option for difficult-to-manage epilepsy cases.
Area of Science:
- Neurology
- Clinical Pharmacology
Background:
- Primary generalised epilepsy is a challenging neurological condition.
- Refractory epilepsy cases often require novel therapeutic strategies.
- Existing antiepileptic drugs (AEDs) may be ineffective in some patients.
Observation:
- Three patients with refractory primary generalised epilepsy were studied.
- All patients exhibited generalised spike wave on EEG and had failed multiple prior AEDs.
- Levetiracetam was administered as monotherapy.
Findings:
- All three patients achieved complete seizure freedom for a minimum of six months.
- Levetiracetam was well-tolerated across all participants.
- Therapeutic levetiracetam doses ranged from 1250 to 3000 mg/day.
Implications:
- Levetiracetam demonstrates significant efficacy in treating refractory primary generalised epilepsy.
- This AED, with its novel mechanism of action, presents a valuable therapeutic option.
- Further investigation into levetiracetam for refractory epilepsy is warranted.